# A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy

> **NCT06821542** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Incyte Corporation** · enrollment: 9 (actual)

## Conditions studied

- Chronic Graft-versus-host-disease

## Interventions

- **DRUG:** INCA034176
- **DRUG:** Best Available Therapy (BAT)

## Key facts

- **NCT ID:** NCT06821542
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-06-04
- **Primary completion:** 2028-05-31
- **Final completion:** 2032-11-30
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2026-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06821542

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06821542, "A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06821542. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*